Physician profile
Janese Laster
NPI 1679839047
$56,927.64
in general payments reported to CMS, 2019-2025
7 companies · $22K in 2025
The $22K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2022: $356 · 2023: $318 · 2024: $35K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $48K · Consulting Fee: $3,769 · Travel and Lodging: $2,962 · Food and Beverage: $1,988.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $47,753.19 |
| Consulting Fee | $3,768.75 |
| Travel and Lodging | $2,961.51 |
| Food and Beverage | $1,987.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $54,326.02 | 2023-2025 | Wegovy |
| Eli Lilly and Company | $1,250.00 | 2024 | |
| Boston Scientific Corporation | $696.99 | 2022-2025 | Overstitch Endoscopic Suturing System, Apollo Revise System, Apollo 2-0 Polypropylene Endobariatric Suture |
| Apollo Endosurgery US INC | $450.41 | 2022-2023 | Overstitch Endoscopic Suturing System |
| Abbvie INC. | $100.89 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $75.00 | 2023 | |
| Lilly USA, LLC | $28.33 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janese Laster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.